Hone Health Raises $228M | $200M Is General Catalyst Growth Financing
Hone Health raised $228M: a $28M Series A extension led by MarcyPen Capital Partners plus $200M in growth financing from General Catalyst's Customer Value Fund.
Company intelligence
As of November 18, 2026, Hone Health has raised at least $228M in equity across 1 sourced funding round. Its most recent revenue figure is crossed $100M, reported by Fierce Healthcare, December 2025.
Hone Health is a New York physician-led longevity platform that announced $228 million in financing on Nov. 18, 2026.
Hone Health is a physician-led longevity platform based in New York. Its own description says it helps people who want more control over how they age to design a personalized plan for their health. The company runs its service online at honehealth.com, where it offers care for men and for women.[1],[2]
Fortune reports that Saad Alam co-founded Hone Health in 2020 as an online clinic that began by treating men with low testosterone. Alam says he started the company after a doctor dismissed his own symptoms at age 35. Fortune also says Hone is the first business under a parent company called Time Therapeutics.[3]
Hone says its care combines biomarker testing, one-on-one physician consultations and personalized treatment. Treatment covers testosterone replacement therapy, menopause hormone therapy, weight management, peptides, thyroid, heart health and sexual health. The company says its clinical platform, Longevity OS, gives physicians a real-time view of each patient's health across specialties.[1]
The company says it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers. Fortune adds that Hone treated about 200,000 patients since it launched. In January 2025 it reported 55,000 patients treated. Fierce Healthcare reports that Hone crossed $100 million in revenue in 2025, per Alam, and is on track to double this year; Fortune also cites Alam on the $100 million mark. The figure comes from the founder and is not audited.[1],[3],[4]
Hone announced $228 million in new financing on Nov. 18, 2026. Fortune reports that $28 million of it is equity, raised as an extension of Hone's Series A rather than a Series B. The other $200 million comes from General Catalyst's Customer Value Fund. Medtech Insight, published by Citeline, describes the same split.[3],[5]
MarcyPen Capital Partners led the equity portion. Fortune describes MarcyPen as the investment firm cofounded by Shawn Carter, known as Jay-Z, with Jay Brown and Robbie and D'Rita Robinson. The announcement also disclosed that MarcyPen led Hone's earlier Series A, a role the company had not made public. Fortune quotes Hone as saying MarcyPen has historically kept a low public profile.[3],[1]
Other equity backers named by Fortune include Kinship Ventures, Pentland Ventures, Hanwha, Gannet Capital and Humbition. Kinship was cofounded by Gwyneth Paltrow and Moj Mahdara. Paltrow told Fortune she is also a patient. The company's release lists Comma Capital and ID Ventures as additional participants. Individual investors include Nick, Joe and Kevin Jonas and Kelly Rowland.[3],[1]
Fortune explains that the Customer Value Fund pays for a large share of a company's sales and marketing and is repaid from the revenue the new customers bring in. Alam said he can ask General Catalyst each month for $10 million, spend it acquiring patients, and repay a portion of the profit from those patients plus interest. He said the deal has no recourse and no covenants restricting Hone from raising other money. The new round brings Hone's total equity funding to $65 million.[3]
The financing follows Hone's $33 million Series A, announced in January 2025. Hone's release says that round supported its expansion beyond hormone health optimization into broader longevity care.[1]
Hone says it will use the investment in five areas. These are broader clinical programs in metabolic health, PMOS, inflammation and immunity, and additional diagnostics, including full-body MRI, DEXA scans, coronary CT angiography and gut microbiome analysis. They also include clinical technology, a physician-supervised peptide program where legally available, and research and trials infrastructure.[1]
Alam told Fortune that most of the $28 million equity will go to technology that lets one physician handle problems that would normally send a patient to several specialists. He described a three-stage plan: build a large online clinic, use its patient base to run clinical trials remotely, then partner with drugmakers and research centers.[3]
Hone is publicly launching Hone Black, a concierge membership that has run quietly for the past year with a select group of high-profile patients. Hone says it combines testing of more than 1,600 health markers with a dedicated team of physicians responsible for whole-body care. Alam calls it a test bed for treatments that may later reach Hone's main product.[1],[3]
Since its January 2025 round, Hone says it has launched a cardiovascular program that evaluates risk using advanced health markers and integrated Prenuvo whole-body MRI and BodySpec DEXA scans.[1]
Is something wrong on this page?
Hone Health is a healthtech company.
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Nov 18, 2026 | Series A extension | $228M | — | MarcyPen Capital Partnersunverified WithGeneral CatalystunverifiedHanwha Asset ManagementunverifiedHumbitionunverifiedPentland VenturesKinship VenturesGannet CapitalComma Capital+1 more | Fitt Insider |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Hone Health has raised at least $228M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $228M Series A extension in November 2026, reported by Fitt Insider. Debt financing, tender offers and secondary sales are not counted.
Lead investors in Hone Health's sourced funding rounds include MarcyPen Capital Partners. Per round: its November 2026 Series A extension was led by MarcyPen Capital Partners.
Hone Health's most recent revenue figure is crossed $100M, reported by Fierce Healthcare, December 2025.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.